Scarica l'app Stockscreener
91.84
0.21%
0.19
Dopo l'orario di chiusura:
91.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$91.65
Aprire:
$92.01
Volume 24 ore:
6.45M
Relative Volume:
1.06
Capitalizzazione di mercato:
$114.43B
Reddito:
$28.30B
Utile/perdita netta:
$126.00M
Rapporto P/E:
1,020.44
EPS:
0.09
Flusso di cassa netto:
$9.43B
1 W Prestazione:
+2.18%
1M Prestazione:
-1.03%
6M Prestazione:
+25.29%
1 anno Prestazione:
+6.20%
Intervallo 1D:
$91.69
$92.80
Intervallo di 1 settimana:
$89.02
$93.07
Portata 52W:
$62.07
$98.90
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
91.84 | 114.43B | 28.30B | 126.00M | 9.43B | 0.09 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Can Gilead Sciences Sustain Its Growth Momentum In 2025? - Barchart
Can Gilead Sciences Sustain Its Growth Momentum in 2025? - Yahoo Finance
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults - PMLiVE
HB Wealth Management LLC Purchases 8,406 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Gilead Sciences Q2 EPS Estimate Boosted by Zacks Research - MarketBeat
Liberty One Investment Management LLC Sells 7,350 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Nexus Investment Management ULC Trims Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Premier Path Wealth Partners LLC Has $744,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Arkadios Wealth Advisors Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Boston Common Asset Management LLC Sells 53,301 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Wedge Capital Management L L P NC Sells 86,409 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Park Avenue Securities LLC Buys 6,878 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $228,375.00 in Stock - MarketBeat
Advanced biologic developer Gilead cites manufacturing efficiencies as CAR-T advantage in 2025 - BioProcess Insider
Gilead Sciences CFO sells shares worth $228,375 - MSN
Earnings Preview: What to Expect From Gilead Sciences’ Report - Nasdaq
Earnings Preview: What To Expect From Gilead Sciences’ Report - Barchart
Occidental Asset Management LLC Acquires 3,980 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Trimmed by Sicart Associates LLC - MarketBeat
Gateway Investment Advisers LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Global Pharma & Biotech CRM Software Market To Surpass Valuation of US$ 20.0 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences - Yahoo Finance
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus.com
Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others - Yahoo Finance
Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy? - Insider Monkey
Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy - FiercePharma
Gilead, US Settle Billion-Dollar Patent Feud Over HIV Drugs (1) - Bloomberg Law
Gilead's Kite taps longtime Amgen alum as new global commercial head - FiercePharma
JPM25 Day 3: AbbVie, Gilead, GSK and Dyne - BioSpace
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - Yahoo Finance
JPM Day 3: AbbVie, Gilead, GSK and Dyne - BioSpace
Rovin Capital UT ADV Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
USA Financial Formulas Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Primary Sclerosing Cholangitis Market Deep Research Report Forecast by 2031 | Acorda Therapeutics, Inc., - EIN News
Gilead And US Settle HIV Drug Patent Dispute - Finimize
Assenagon Asset Management S.A. Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead, Feds Resolve HIV Drug Patent Dispute Amid Appeal - Law360
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance
Gilead reportedly settles CDC patent dispute over HIV drugs - Seeking Alpha
Gilead Sciences Inc. stock rises Wednesday, still underperforms market - MarketWatch
Biden administration and Gilead settle long-running battle over patents for HIV PrEP pills - STAT
Gilead Sciences, US government settle patent case over HIV prevention drugs - MSN
Autologous Cell Therapy Market Set to Witness Significant Growth by 2025-2032: Bristol Myers Squibb, Gilead - EIN News
40 Under 40: Rasika Iyer, Gilead Sciences - MM+M Online
April 17th Options Now Available For Gilead Sciences (GILD) - Nasdaq
Global Financial Private Client LLC Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Wright Investors Service Inc. Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch
Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies - GuruFocus.com
LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):